Answers are grounded in this paper and cite their sources.
The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam-durlobactam-based antibiotic regimen. We also performed a longitudinal genomic analysis of the bacterial isolates and showed the development of resistance and genetic mutations over time.
No takes yet. Share an insight, caveat, or question.
VanNatta et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: